HAVCR2 and B-cell chronic lymphocytic leukemia: In a recent study, the inhibition of the TIM-3/galectin-9 pathway suppressed the function of regulatory T cells, suggesting that this pathway could be a novel target for immunotherapy in patients with CLL [16].